Relapsed Pediatric AML research hub

Vyxeos® With Clofarabine for Pediatric AML

This study looks at a new combination of medicines, Vyxeos and clofarabine, for children and young adults aged 1 to 21 with acute myeloid leukaemia (AML) that has come back or hasn't responded to previous treatments.